Enoblituzumab, previously known as TJ-271 or MGA271, represents an innovative therapeutic specific to CD33, an antigen found predominantly on blood tissues. Such agent operates as the two-pronged construct, https://nellteqj946244.blog5.net/93295629/enoblituzumab-a-deep-dive-into-tj-271-and-mga271